SB 4525, the “Securing Innovation and Research from Adversaries Act,” would bar the use of federal research funds for collaborations involving entities or individuals on a broad set of U.S. government restricted lists. The prohibition applies to any person or organization participating in a federally funded research award and covers joint research projects, co-authored publications, data sharing, material transfers, joint labs, personnel exchanges, and similar arrangements. The bill is aimed at preventing federally supported research from benefiting foreign adversaries or other restricted actors.
The bill also directs the Director of the Office of Science and Technology Policy, working with relevant federal research agencies, to issue government-wide guidance so agencies use standardized compliance rules, definitions, and enforcement mechanisms. In addition, it creates a waiver process allowing agency heads to approve exceptions on a case-by-case basis when necessary for U.S. national security or when the collaboration is essential for a clearly defined scientific, public health, or national security purpose that cannot reasonably be achieved otherwise. Any waiver must be reported to Congress within 30 days, including the identity of the subject, the justification, and mitigation measures.
The bill would affect federal grant, contract, cooperative agreement, and other research funding arrangements, including awards made under other transaction authority. It would also define “restricted entity lists” broadly to include Commerce, Treasury, State, FCC, and other federal lists, as well as several China-related lists involving military companies, telecommunications firms, academic institutions, semiconductor companies, biotechnology companies of concern, and entities tied to forced labor or securities restrictions. As drafted, the measure would likely require universities, laboratories, contractors, and other research recipients to screen collaborators more aggressively and potentially alter international research partnerships.
The available context shows no committee transcript, no recorded votes, and no formal opposition or support statements, so the overall sentiment cannot be measured from debate history. Based on the bill text, the measure appears to be framed as a national security and research integrity initiative rather than a partisan or procedural change. The inclusion of a waiver process suggests an attempt to balance security concerns with scientific and public health collaboration needs.
The main point of contention likely concerns how broadly the restrictions reach and whether they could chill legitimate scientific cooperation, especially with foreign universities, researchers, and companies that appear on or are connected to restricted lists. Another likely issue is administrative burden, since the bill would require agencies and research recipients to interpret multiple evolving federal lists and compliance standards. Supporters would likely emphasize protection against espionage, technology transfer, and adversarial influence, while critics may worry about overbreadth and impacts on open research.
The bill would add a new federal restriction on the use of federally funded research dollars, prohibiting covered recipients from using those funds to collaborate with entities or individuals tied to a wide range of federal restricted lists. It would require OSTP to issue uniform implementation guidance and would create a waiver-and-reporting framework for exceptions. In practice, it would likely increase compliance obligations for universities, laboratories, contractors, and other recipients of federal research awards, and could limit or reshape international research partnerships, especially those involving China-related or otherwise sanctioned entities.
There is no recorded vote or committee debate in the provided materials, so no direct legislative sentiment can be measured. The bill’s framing suggests a generally security-focused posture, with the title and text emphasizing protection of innovation and research from adversaries. The presence of a waiver mechanism indicates some recognition that certain collaborations may still be necessary for scientific, public health, or national security reasons.
The likely contention centers on the breadth of the prohibited collaborations and the scope of the restricted entity lists, which include multiple sanctions, export-control, defense, telecommunications, semiconductor, biotechnology, and forced-labor-related lists. Critics would likely argue that the bill could sweep in legitimate academic and scientific partnerships and impose significant compliance costs, while supporters would argue that those restrictions are necessary to prevent federal research funds from aiding foreign adversaries and to protect national security. The waiver authority may also be debated as either a needed safety valve or an insufficient exception to an otherwise broad prohibition.